Millipore Sigma

Jan 14, 2025 | cellandgene.com | Tyler Menichiello |Caitlyn Smith |Ratish Krishnan |Millipore Sigma

Webinar: The Next Frontier in mRNA: Modular Manufacturing for Scalable RNA-LNP TherapiesmRNA therapeutic manufacturers face challenges around mRNA products encapsulated in lipid nanoparticles (LNPs). Learn more about the Centre for Process Innovation’s first UK GMP-ready site, and how it meets diverse RNA product demands.

Dec 4, 2024 | advancingrna.com | Tyler Menichiello |Conner Feldman |Millipore Sigma |Optimizing mRNA

Leading experts in gene therapy discuss CMC strategy for platform technologies, product lifecycle management, and the role CDMOs play in moving the space forward. This segment features a discussion around the obstacles to establishing a standardized production pipeline for mRNA therapeutics across the industry as well as some the approaches being considered to standardize cold chain management protocols for mRNA products.

Dec 2, 2024 | biopharmadive.com | Millipore Sigma

An article from Permission granted by MilliporeSigma SPONSORED CONTENT BY Evolving technology has helped advance the field of gene therapy, and today, more and more biopharmaceutical innovators are using groundbreaking approaches to treat diseases. Adeno-associated virus (AAV) vectors have emerged as a leading gene-delivery tool[1], with several AAV-based therapeutics approved by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA).

Nov 26, 2024 | chromatographyonline.com | Millipore Sigma

November 26, 2024NewsArticleSponsored ContentUltrapure water from a Milli-Q® water purification system was tested for PFAS according to the draft EPA 1633 method. None of the 40 PFAS compounds tested were detected in the ultrapure water produced by a Milli-Q® IQ 7000 systemfitted with a LC-Pak® polisher at the point-of-dispense, making it suitable for the most sensitive PFAS analyses by LC-MS/MS. Related Content Related Content

Oct 29, 2024 | money.mymotherlode.com | Millipore Sigma

Triples manufacturing capacity to meet increased global demand for antibody-drug conjugates (ADCs) Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America Expansion to create 170 jobs at Bioconjugation Center of Excellence in St. Louis, Missouri MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, today announced a $76 million expansion of its ADC manufacturing capabilities...